Dr Mark Boyd

Mak G; Zaunders JJ; Bailey M; Seddiki N; Rogers G; Leong L; Phan TG; Kelleher AD; Koelsch KK; Boyd MA; Danta M, 2021, 'Preservation of Gastrointestinal Mucosal Barrier Function and Microbiome in Patients With Controlled HIV Infection', Frontiers in Immunology, vol. 12, http://dx.doi.org/10.3389/fimmu.2021.688886

Khaw C; Zablotska-Manos I; Boyd MA, 2020, 'Men who have Sex with Men and Chemsex: A Clinic-Based Cross-sectional Study in South Australia', Sexuality Research and Social Policy, http://dx.doi.org/10.1007/s13178-020-00505-2

Mwasakifwa GE; Amin J; White CP; Center JR; Kelleher A; Boyd MA, 2020, 'Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study', HIV Medicine, vol. 21, pp. 492 - 504, http://dx.doi.org/10.1111/hiv.12882

Lau A; Kong FYS; Fairley CK; Templeton DJ; Amin J; Boyd MA; Bradshaw C; Chen MY; Donovan B; Khaw C; Lewis DA; McNulty A; Regan DG; Ratnayake M; Hocking JS, 2020, 'Factors Associated with Early Resumption of Condomless Anal Sex among Men Who Have Sex with Men after Rectal Chlamydia Treatment', Sexually Transmitted Diseases, vol. 47, pp. 389 - 394, http://dx.doi.org/10.1097/OLQ.0000000000001166

Yang F; Janamnuaysook R; Boyd MA; Phanuphak N; Tucker JD, 2020, 'Key populations and power: people-centred social innovation in Asian HIV services', The Lancet HIV, vol. 7, pp. e69 - e74, http://dx.doi.org/10.1016/S2352-3018(19)30347-9

Vannakit R; Andreeva V; Mills S; Cassell MM; Jones MA; Murphy E; Ishikawa N; Boyd MA; Phanuphak N, 2020, 'HIV programmes in countries within the Asia-Pacific region - Authors' reply.', Lancet HIV, vol. 7, pp. e530 - e531, http://dx.doi.org/10.1016/S2352-3018(20)30210-1

Khaw C; Malden C; Ratnayake M; Boyd M, 2020, 'Diagnosis and Management of Syphilis in Patients With HIV Co-infection', Current Treatment Options in Infectious Diseases, vol. 12, pp. 215 - 226, http://dx.doi.org/10.1007/s40506-020-00225-6

Vannakit R; Andreeva V; Mills S; Cassell MM; Jones MA; Murphy E; Ishikawa N; Boyd MA; Phanuphak N, 2020, 'Fast-tracking the end of HIV in the Asia Pacific region: domestic funding of key population-led and civil society organisations.', Lancet HIV, vol. 7, pp. e366 - e372, http://dx.doi.org/10.1016/S2352-3018(20)30077-1

Ramachandran J; Kaambwa B; Muller K; Haridy J; Tse E; Tilley E; Altus R; Waddell V; Gordon D; Shaw D; Huynh D; Stewart J; Nelson R; Warner M; Boyd MA; Chinnaratha MA; Harding D; Ralton L; Colman A; Woodman R; Wigg AJ, 2020, 'Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience.', Eur J Gastroenterol Hepatol, vol. 32, pp. 1381 - 1389, http://dx.doi.org/10.1097/MEG.0000000000001659

Melaku YA; Gill TK; Appleton SL; Hill C; Boyd MA; Adams RJ, 2019, 'Sociodemographic, lifestyle and metabolic predictors of all-cause mortality in a cohort of community-dwelling population: an 18-year follow-up of the North West Adelaide Health Study.', BMJ Open, vol. 9, pp. e030079, http://dx.doi.org/10.1136/bmjopen-2019-030079

McManus H; Callander D; Donovan B; Russell DB; O'Connor CC; Davies SC; Lewis DA; Hellard ME; Chen MY; Petoumenos K; Varma R; Cogle A; Boyd MA; Grulich A; Pollard J; Medland N; Fairley CK; Guy RJ, 2019, 'Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia: trends and predictors, 2004–2015', Medical Journal of Australia, vol. 210, pp. 269 - 275, http://dx.doi.org/10.5694/mja2.50006

Boyd MA; Boffito M; Castagna A; Estrada V, 2019, 'Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps', HIV Medicine, vol. 20, pp. 3 - 11, http://dx.doi.org/10.1111/hiv.12708

Ramachandran J; Kaambwa B; Muller K; Haridy J; Tse E; Tilley E; Waddell V; Gordon D; Shaw D; Nelson R; boyd M; Warner M; Ralton L; Colman A; stewart J; Harding D; Chinnaratha A; Woodman R; Huynh D; Wigg A, 2019, 'FRI-200-Spend less get more;cost effectiveness of various models of care in hepatitis C treatment', Journal of Hepatology, vol. 70, pp. e479 - e479, http://dx.doi.org/10.1016/s0618-8278(19)30945-4

Bell SK; Mena G; Dean J; Watts P; Howard C; Boyd M; Gilks C; Gartner C, 2019, 'Addressing smoking among people living with HIV: a cross-sectional survey of Australian HIV health practitioners' practices and attitudes.', AIDS Care, vol. 31, pp. 436 - 442, http://dx.doi.org/10.1080/09540121.2018.1500007

Giles ML; Gartner C; Boyd MA, 2018, 'Smoking and HIV: What are the risks and what harm reduction strategies do we have at our disposal?', AIDS Research and Therapy, vol. 15, http://dx.doi.org/10.1186/s12981-018-0213-z

Wright E; Grulich A; Roy K; Boyd M; Cornelisse V; Russell D; O'Donnell D; Whittaker B; Crooks L; Zablotska I, 2018, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.', J Virus Erad, vol. 4, pp. 143 - 159, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892678/

Stockdale AJ; Saunders MJ; Boyd MA; Bonnett LJ; Johnston V; Wandeler G; Schoffelen AF; Ciaffi L; Stafford K; Collier AC; Paton NI; Geretti AM, 2018, 'Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis', Clinical Infectious Diseases, vol. 66, pp. 1846 - 1857, http://dx.doi.org/10.1093/cid/cix1108

Wright E; Grulich A; Roy K; Boyd M; Cornelisse V; Russell D; O'Donnell D; Whittaker B; Crooks L; Zablotska I, 2018, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.', Journal of Virus Eradication, vol. 4, pp. 143 - 159

Boyd MA; Cooper DA, 2018, 'Combination ART: are two drugs as good as three?', The Lancet, vol. 391, pp. 817 - 819, http://dx.doi.org/10.1016/S0140-6736(18)30008-4

Mwasakifwa GE; Moore C; Carey D; Amin J; Penteado P; Losso M; Lim PL; Mohapi L; Molina JM; Gazzard B; Cooper DA; Boyd M, 2018, 'Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy', AIDS, vol. 32, pp. 357 - 361, http://dx.doi.org/10.1097/QAD.0000000000001688

Boyd MA; Cooper DA; Gilks CF, 2018, 'Towards a universal second-line fixed-dose combination ART', The Lancet HIV, vol. 5, pp. e3 - e5, http://dx.doi.org/10.1016/S2352-3018(17)30180-7

Yao AH; Moore CL; Lim PL; Molina JM; Madero JS; Kerr S; Mallon PWG; Emery S; Cooper DA; Boyd MA, 2018, 'Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial', Antiviral Therapy, vol. 23, pp. 21 - 32, http://dx.doi.org/10.3851/IMP3171

Wright E; Grulich A; Roy K; Boyd M; Cornelisse V; Russell D; O'Donnell D; Whittaker B; Crooks L; Zablotska I, 2018, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018', Journal of Virus Eradication, vol. 4, pp. 143 - 159, http://dx.doi.org/10.1016/s2055-6640(20)30260-0

Haridy J; Wigg A; Muller K; Ramachandran J; Tilley E; Waddell V; Gordon D; Shaw D; Huynh D; Stewart J; Nelson R; Warner M; Boyd M; Chinnaratha MA; Harding D; Ralton L; Colman A; Liew D; Iyngkaran G; Tse E; Adelaide Liver Group , 2018, 'Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience.', J Viral Hepat, vol. 25, pp. 1287 - 1297, http://dx.doi.org/10.1111/jvh.12943

Haridy J; Wigg A; Muller K; Ramachandran J; Tilley E; Waddell V; Gordon D; Shaw D; Huynh D; Stewart J; Nelson R; Warner M; Boyd M; Chinnaratha A; Harding D; Ralton L; Colman A; Iyngkaran G; Tse E, 2018, 'Outcomes of direct-acting antiviral therapy for chronic hepatitis C following unrestricted access in Australia: Real-world outcomes from the state of South Australia', Journal of Hepatology, vol. 68, pp. S265 - S265, http://dx.doi.org/10.1016/s0168-8278(18)30743-8

Boyd MA; Mocroft A; Ryom L; Monforte AD; Sabin C; El-Sadr WM; Hatleberg CI; De Wit S; Weber R; Fontas E; Phillips A; Bonnet F; Reiss P; Lundgren J; Law M, 2017, 'Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study', PLoS Medicine, vol. 14, http://dx.doi.org/10.1371/journal.pmed.1002424

Puhr R; Petoumenos K; Youds D; Law MG; Templeton DJ; Ellis D; Bloch M; Agrawal S; Vincent T; Allen D; Smith D; Rankin A; Baker D; O'Connor CC; Thackeray O; Jackson E; McCallum K; Ryder N; Sweeney G; Cooper D; Carr A; Macrae K; Hesse K; Finlayson R; Gupta S; Langton-Lockton J; Shakeshaft J; Brown K; Idle S; Arvela N; Varma R; Lu H; Couldwell D; Eswarappa S; Smith DE; Furner V; Cabrera G; Fernando S; Cogle A; Lawrence C; Mulhall B; Boyd M; Law M; Huang R; Han A; Gunathilake M; Payne R; O'Sullivan M; Croydon A; Russell D; Cashman C; Roberts C; Sowden D; Taing K; Marshall P; Orth D; Rowling D; Latch N; Warzywoda E; Dickson B; Donohue W; Moore R; Edwards S; Boyd S; Roth NJ; Lau H; Read T; Silvers J; Zeng W; Hoy J; Watson K; Bryant M; Price S; Woolley I; Giles M; Korman T; Williams J; Nolan D; Allen A; Guelfi G; Mills G; Wharry C; Raymond N; Bargh K, 2017, 'The impact of changes in HIV management guidelines on time to treatment initiation in Australia', HIV Medicine, vol. 18, pp. 701 - 703, http://dx.doi.org/10.1111/hiv.12504

Boyd MA; Cooper DA, 2017, 'Long-acting injectable ART: next revolution in HIV?', The Lancet, vol. 390, pp. 1468 - 1470, http://dx.doi.org/10.1016/S0140-6736(17)31962-1

Thit SS; Aung NM; Htet ZW; Boyd MA; Saw HA; Anstey NM; Kyi TT; Cooper DA; Kyi MM; Hanson JP, 2017, 'The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study.', BMC Medicine, vol. 15, http://dx.doi.org/10.1186/s12916-017-0888-3

Bell SK; Mena G; Dean J; Boyd M; Gilks C; Gartner C, 2017, 'Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners' attitudes.', Drug Alcohol Depend, vol. 177, pp. 67 - 70, http://dx.doi.org/10.1016/j.drugalcdep.2017.03.023

Bell S; Dean J; Gilks C; Boyd MA; Fitzgerald L; Mutch A; Baker P; Neilsen G; Gartner CE, 2017, 'Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke.', Int J Environ Res Public Health, vol. 14, http://dx.doi.org/10.3390/ijerph14070799

Wright E; Grulich A; Roy K; Boyd M; Cornelisse V; Russell D; O'Donnell D; Whittaker B; Crooks L; Zablotska I, 2017, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines', JOURNAL OF VIRUS ERADICATION, vol. 3, pp. 168 - 184, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000419211600011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Boyd MA, 2017, 'Body composition substudy of the SECOND-LINE study – Author's reply', The Lancet HIV, vol. 4, pp. e240, http://dx.doi.org/10.1016/S2352-3018(17)30093-0

Rhee SY; Varghese V; Holmes SP; Van Zyl GU; Steegen K; Boyd MA; Cooper DA; Nsanzimana S; Saravanan S; Charpentier C; de Oliveira T; Etiebet MAA; Garcia F; Goedhals D; Gomes P; Günthard HF; Hamers RL; Hoffmann CJ; Hunt G; Jiamsakul A; Kaleebu P; Kanki P; Kantor R; Kerschberger B; Marconi VC; D'amour Ndahimana J; Ndembi N; Ngo-Giang-Huong N; Rokx C; Santoro MM; Schapiro JM; Schmidt D; Seu L; Sigaloff KCE; Sirivichayakul S; Skhosana L; Sunpath H; Tang M; Yang C; Carmona S; Gupta RK; Shafer RW, 2017, 'Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration', EBioMedicine, vol. 18, pp. 225 - 235, http://dx.doi.org/10.1016/j.ebiom.2017.03.024

Aung NM; Hanson J; Kyi TT; Htet ZW; Cooper DA; Boyd MA; Kyi MM; Saw HA, 2017, 'HIV care in Yangon, Myanmar; successes, challenges and implications for policy', AIDS Research and Therapy, vol. 14, http://dx.doi.org/10.1186/s12981-017-0137-z

Lau A; Kong F; Fairley CK; Donovan B; Chen M; Bradshaw C; Boyd M; Amin J; Timms P; Tabrizi S; Regan DG; Lewis DA; McNulty A; Hocking JS, 2017, 'Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol', BMC Infectious Diseases, vol. 17, http://dx.doi.org/10.1186/s12879-016-2125-7

Boyd MA; Amin J; Mallon PWG; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA, 2017, 'Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study', The Lancet HIV, vol. 4, pp. e13 - e20, http://dx.doi.org/10.1016/S2352-3018(16)30189-8

Petoumenos K; Choi JY; Hoy J; Kiertiburanakul S; Ng OT; Boyd M; Rajasuriar R; Law M, 2017, 'CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy', Antiviral Therapy, vol. 22, pp. 659 - 668, http://dx.doi.org/10.3851/IMP3155

Boyd M; Cooper D; Crock EA; Crooks L; Giles ML; Grulich A; Lewin SR; Nolan D; Yarwood T, 2016, 'Sexual transmission of HIV and the law: An Australian medical consensus statement', Medical Journal of Australia, vol. 205, pp. 409 - 412, http://dx.doi.org/10.5694/mja16.00934

Zaunders J; Danta M; Bailey M; Mak G; Marks K; Seddiki N; Xu Y; Templeton DJ; Cooper DA; Boyd MA; Kelleher AD; Koelsch KK, 2016, 'CD4⁺ T follicular helper and IgA⁺ B cell numbers in gut biopsies from HIV-infected subjects on antiretroviral therapy are similar to HIV-uninfected individuals', Frontiers in Immunology, vol. 7, http://dx.doi.org/10.3389/fimmu.2016.00438

Lam EP; Moore CL; Gotuzzo E; Nwizu C; Kamarulzaman A; Chetchotisakd P; Van Wyk J; Teppler H; Kumarasamy N; Molina JM; Emery S; Cooper DA; Boyd MA, 2016, 'Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study', AIDS Research and Human Retroviruses, vol. 32, pp. 841 - 850, http://dx.doi.org/10.1089/aid.2015.0331

Achhra AC; Mwasakifwa G; Amin J; Boyd MA, 2016, 'Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis', The Lancet HIV, vol. 3, pp. e351 - e360, http://dx.doi.org/10.1016/S2352-3018(16)30015-7

Boyd MA; Cooper DA, 2016, 'Tenofovir alafenamide: safer, but questions remain', The Lancet HIV, vol. 3, pp. e148 - e149, http://dx.doi.org/10.1016/S2352-3018(16)00039-4

Arts E; Boyd M, 2016, 'Reviewer acknowledgement.', AIDS Res Ther, vol. 13, pp. 13, http://dx.doi.org/10.1186/s12981-016-0097-8

Boyd MA; Cooper DA, 2016, 'Novel antiretroviral agents and universal access to HIV care', The Lancet HIV, vol. 3, pp. e2 - e3, http://dx.doi.org/10.1016/S2352-3018(15)00244-1

Alvarez E; Belloso WH; Boyd MA; Inkaya AC; Hsieh E; Kambugu A; Kaminski G; Martinez E; Stellbrink HJ; Walmsley S; Brown TT; Mallon PWG, 2016, 'Which HIV patients should be screened for osteoporosis: An international perspective', Current Opinion in HIV and AIDS, vol. 11, pp. 268 - 276, http://dx.doi.org/10.1097/COH.0000000000000269

Arts E; Boyd M, 2016, 'Reviewer acknowledgement.', AIDS Res Ther, vol. 13, pp. 13, http://dx.doi.org/10.1186/s12981-016-0097-8

Lambert-Niclot S; George EC; Pozniak A; White E; Schwimmer C; Jessen H; Johnson M; Dunn D; Perno CF; Clotet B; Plettenberg A; Blaxhult A; Palmisano L; Wittkop L; Calvez V; Marcelin AG; Raffi F; NEAT 001/ANRS 143 Study Group , 2016, 'Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.', J Antimicrob Chemother, vol. 71, pp. 1056 - 1062, http://dx.doi.org/10.1093/jac/dkv427

Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H; Renjifo B; Molina JM; Emery S; Cooper DA, 2015, 'Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS ONE (2015)10:2 (e0118228) Doi: 10.1371/journal.pone.0118228 ))', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0140623

Boyd MA; Cooper DA, 2015, 'The LATTE study: A provocative brew', The Lancet Infectious Diseases, vol. 15, pp. 1116 - 1117, http://dx.doi.org/10.1016/S1473-3099(15)00224-8

Templeton DJ; Wright ST; McManus H; Lawrence C; Russell DB; Law MG; Petoumenos K; Ellis D; Bloch M; Agrawal S; Vincent T; Allen D; Smith D; Allardice K; Baker D; Odgers E; O'Connor CC; Phan S; Jackson E; McCallum K; Grotowski M; Ryder N; Taylor S; Cooper D; Carr A; Lee F; McRae K; Hesse K; Finlayson R; Gupta S; Varma R; Shakeshaft J; Brown K; McGrath V; Halligan S; Arvela N; Wray L; Thng C; Foster R; Lu H; Couldwell D; DSmith E; Furner V; Fernando S; Dubbo ; Watson J; Mulhall B; Wright S; Bendall C; Boyd M; Gunathilake M; Payne R; O'Sullivan M; White S; Russell D; Joslin J; Cashman C; Sowden D; Taing K; McGill K; Orth D; Youds D; Kelly M; Rowling D; Latch N; Warzywoda E; Dickson B; Donohue W; Moore R; Edwards S; Boyd S; N.Roth J; Lau H; Read T; Silvers J; Zeng W; Hoy J; Watson K; Bryant M; Price S; Woolley I; Giles M; Korman T; Williams J; Nolan D; Guelfi G; Mills G; Wharry C; Raymond N; Bargh K; Morwood K; Roth N; Choong K, 2015, 'Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)', BMC Infectious Diseases, vol. 15, http://dx.doi.org/10.1186/s12879-015-1051-4

Cummins NW; Neuhaus J; Chu H; Neaton J; Wyen C; Rockstroh JK; Skiest DJ; Boyd MA; Khoo S; Rotger M; Telenti A; Weinshilboum R; Badley AD, 2015, 'Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis', EBioMedicine, vol. 2, pp. 706 - 712, http://dx.doi.org/10.1016/j.ebiom.2015.05.012

Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Foulkes S; Hill A; Jessen H; Kumar S; Lee MP; Nwizu C; Read T; Rooney J; Schaffer K; Shahar E; Winston A; Wolff M; Young B; Abela C; Avihingsanon A; Boyd M; Carey D; Clarke A; Courtney-Vega K; Delfino M; Donaldson A; Emery S; Espinosa N; Johannesen T; Lin E; Losso M; Moricz A; Pett S; Phanupak P; Puls R; Pussadee K; Sutheerasak P; Tomlins L; Ubolyam S; bin Raja Azwa RIS; Bissio E; Calanni L; Chetchotisakd P; Doong N; Elliott J; Gazzard B; Kelly M; Laplume H; del Carmen Luna N; Lupo S; Messina OG; Mohapi L; Moore R; Nolan D; Orrell C; Perez C; Phanuphak P; Rockstroh J; Rowling D; Supparatpinyo K; Smith D; Villanueva JA; Vlahakis E; Kelleher T; Cunningham P; Merlin K; Yeung J; Shaik A; Fsadni B; Carrera A; Lograsso M; Gulick R; Dunn D; Dolan M, 2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, vol. 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5

Han N; Wright ST; O'Connor CC; Hoy J; Ponnampalavanar S; Grotowski M; Zhao HX; Kamarulzaman A; Ellis D; Bloch M; Franic T; Agrawal S; McCann L; Cunningham N; Vincent T; Allen D; Little JL; Smith D; Gray C; Baker D; Vale R; Templeton DJ; Dijanosic C; Jackson E; McCallum K; Taylor S; Cooper D; Carr A; Lee F; Hesse K; Sinn K; Norris R; Finlayson R; Prone I; Shakeshaft J; Brown K; McGrath C; McGrath V; Halligan S; Wray L; Read P; Lu H; Couldwell D; Furner V; Watson J; Lawrence C; Mulhall B; Law M; Petoumenos K; McManus H; Bendall C; Boyd M; Kulatunga A; Knibbs P; Chuah J; Ngieng M; Dickson B; Russell D; Downing S; Sowden D; Broom J; Taing K; Johnston C; McGill K; Orth D; Youds D; Kelly M; Gibson A; Magon H; Donohue W; Moore R; Edwards S; Liddle R; Locke P; Roth NJ; Nicolson J; Lau H; Read T; Silvers J; Zeng W; Watson K; Bryant M; Price S; Woolley I; Giles M; Korman T; Williams J; Nolan D; Skett J; Robinson J; Mean CV; Saphonn V; Vohith K; Zhang FJ; Li PCK; Lee MP; Kumarasamy N; Saghayam S; Ezhilarasi C; Pujari S, 2015, 'HIV and aging: Insights from the Asia Pacific HIV Observational Database (APHOD)', HIV Medicine, vol. 16, pp. 152 - 160, http://dx.doi.org/10.1111/hiv.12188

Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H; Renjifo B; Molina JM; Emery S; Cooper DA, 2015, 'Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0118228

Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA, 2015, 'Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis', The Lancet HIV, vol. 2, pp. e42 - e51, http://dx.doi.org/10.1016/S2352-3018(14)00061-7

Boyd MA; Donovan B; Prestage G; Chen M; Petoumenos K; Gray R; Guy R; Rogers GB; Bourne C; Klausner JD, 2015, 'Is it time to rethink syphilis control?', Clinical Infectious Diseases, vol. 60, pp. 325 - 326, http://dx.doi.org/10.1093/cid/ciu813

McManus H; Hoy JF; Woolley I; Boyd MA; Kelly MD; Mulhall B; Roth NJ; Petoumenos K; Law MG, 2015, 'Erratum: Recent trends in early stage response to combination antiretroviral therapy in Australia', Antiviral Therapy, vol. 20, pp. 255, http://dx.doi.org/10.3851/IMP2822

McManus H; Hoy JF; Woolley I; Boyd MA; Kelly MD; Mulhall B; Roth NJ; Petoumenos K; Law MG, 2015, 'Recent trends in early stage response to combination antiretroviral therapy in Australia', Antiviral Therapy, vol. 20, pp. 131 - 139, http://dx.doi.org/10.3851/IMP2774

Raffi F; Babiker AG; Richert L; Molina JM; George EC; Antinori A; Arribas JR; Grarup J; Hudson F; Schwimmer C; Saillard J; Wallet C; Jansson PO; Allavena C; Van Leeuwen R; Delfraissy JF; Vella S; Chêne G; Pozniak A, 2014, 'Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial', The Lancet, vol. 384, pp. 1942 - 1951, http://dx.doi.org/10.1016/S0140-6736(14)61170-3

Holt SG; Gracey DM; Levy MT; Mudge DW; Irish AB; Walker RG; Baer R; Sevastos J; Abbas R; Boyd MA, 2014, 'A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection', AIDS Research and Therapy, vol. 11, http://dx.doi.org/10.1186/1742-6405-11-35

Haskelberg H; Mallon PWG; Hoy J; Amin J; Moore C; Phanuphak P; Ferret S; Belloso WH; Boyd MA; Cooper DA; Emery S, 2014, 'Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy', Journal of Acquired Immune Deficiency Syndromes, http://dx.doi.org/10.1097/QAI.0000000000000288

Achhra AC; Boyd MA; Law MG; Matthews GV; Kelleher AD; Cooper DA, 2014, 'Moving away from ritonavir, abacavir, tenofovir, and efavirenz (RATE) - Agents that concern prescribers and patients: A feasibility study and call for a trial', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0099530

Haskelberg H; Pocock N; Amin J; Ebeling PR; Emery S; Carr A, 2014, 'Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0094858

Revell AD; Boyd MA; Wang D; Emery S; Gazzard B; Reiss P; van Sighem A; Montaner JS; Lane HC; Larder BA, 2014, 'A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy', HIV Medicine, vol. 15, pp. 442 - 448, http://dx.doi.org/10.1111/hiv.12156

Haskelberg H; Mallon PWG; Hoy J; Amin J; Moore C; Phanuphak P; Ferret S; Belloso WH; Boyd MA; Cooper DA; Emery S, 2014, 'Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ ritonavir compared with standard second-line therapy', Journal of Acquired Immune Deficiency Syndromes, vol. 67, pp. 161 - 168, http://dx.doi.org/10.1097/QAI.0000000000000288

Wright ST; Hoy J; Mulhall B; OʼConnor CC; Petoumenos K; Read T; Smith D; Woolley I; Boyd MA, 2014, 'Determinants of Viremia Copy-Years in People With HIV/AIDS After Initiation of Antiretroviral Therapy', JAIDS Journal of Acquired Immune Deficiency Syndromes, vol. 66, pp. 55 - 64, http://dx.doi.org/10.1097/QAI.0000000000000125

Achhra AC; Boyd MA, 2013, 'Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: A review of the recent literature', AIDS Research and Therapy, vol. 10, http://dx.doi.org/10.1186/1742-6405-10-33

Boyd MA; Cooper DA, 2013, 'SPRING-2 the future of antiretroviral therapy', The Lancet Infectious Diseases, vol. 13, pp. 908 - 909, http://dx.doi.org/10.1016/S1473-3099(13)70194-4

Martin A; Moore C; Mallon PWG; Hoy J; Emery S; Belloso W; Phanuphak P; Ferret S; Cooper DA; Boyd MA, 2013, 'Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy', AIDS, vol. 27, pp. 2403 - 2411, http://dx.doi.org/10.1097/01.aids.0000432534.47217.b4

Byakwaga H; Petoumenos K; Ananworanich J; Zhang F; Boyd MA; Sirisanthana T; Li PCK; Lee C; Mean CV; Saphonn V; Omar SFS; Pujari S; Phanuphak P; Lim PL; Kumarasamy N; Chen YMA; Merati TP; Sungkanuparph S; Ditangco R; Oka S; Tau G; Zhou J; Law MG; Emery S, 2013, 'Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: Results from the TREAT Asia HIV Observational Database', Journal of the International Association of Providers of AIDS Care, vol. 12, pp. 270 - 277, http://dx.doi.org/10.1177/1545109712469684

Wright S; Boyd MA; Yunihastuti E; Law M; Sirisanthana T; Hoy J; Pujari S; Lee MP; Petoumenos K, 2013, 'Rates and Factors Associated with Major Modifications to First-Line Combination Antiretroviral Therapy: Results from the Asia-Pacific Region', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0064902

Jansson J; Wilson DP; Carr A; Petoumenos K; Boyd MA, 2013, 'Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV', AIDS, vol. 27, pp. 1245 - 1251, http://dx.doi.org/10.1097/QAD.0b013e32835e163d

Boyd MA; Donovan B, 2013, 'Antiretroviral therapy: Dolutegravir sets SAIL(ING)', The Lancet, vol. 382, pp. 664 - 666, http://dx.doi.org/10.1016/S0140-6736(13)61456-7

Suzuki K; Hattori S; Marks K; Ahlenstiel C; Maeda Y; Ishida T; Millington M; Boyd M; Symonds G; Cooper DA; Okada S; Kelleher AD, 2013, 'Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing', Molecular Therapy - Nucleic Acids, vol. 2, pp. e137, http://dx.doi.org/10.1038/mtna.2013.64

Martin A; Moore CL; Mallon PWG; Hoy JF; Emery S; Belloso WH; Phanuphak P; Ferret S; Cooper DA; Boyd MA; Second-Line Study Team , 2013, 'HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.', PloS one, vol. 8, http://dx.doi.org/10.1371/journal.pone.0077138

Schneider K; Nwizu CA; Kaplan R; Anderson JS; Wilson DP; Emery S; Cooper DA; Boyd MA, 2013, 'The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa', PLoS ONE, vol. 8, pp. e54435, http://dx.doi.org/10.1371/journal.pone.0054435

Wright ST; Petoumenos K; Boyd MA; Carr AD; Downing S; O''connor C; Grotowski M; Law MG, 2013, 'Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience', HIV Medicine, vol. 14, pp. 208 - 216, http://dx.doi.org/10.1111/j.1468-1293.2012.01053.x

Boyd MA, 2013, 'Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, open-label, non-inferiority study', Lancet, vol. 381, pp. 2091 - 2099, http://dx.doi.org/10.1016/S0140-6736(13)61164-2

Jansson J; Wilson D; Carr A; Petoumenos K; Boyd M, 2012, 'Currently available medications may not be sufficient for lifelong treatment of HIV', JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, vol. 15, pp. 4 - 4, http://dx.doi.org/10.7448/IAS.15.6.18077

Haskelberg H; Hoy J; Amin J; Ebeling PR; Emery S; Carr AD, 2012, 'Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine', PLoS ONE, vol. 7, pp. e38377, http://dx.doi.org/10.1371/journal.pone.0038377

Boyd MA; Cooper DA, 2012, 'Optimisation of HIV care and service delivery: doing more with less', Lancet, vol. 380, pp. 1860 - 1866, http://dx.doi.org/10.1016/S0140-6736(12)61154-4

Carey DL; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray J; Boyd MA; Emery S; Cooper DA, 2012, 'A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults', JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 60, pp. 143 - 149, http://dx.doi.org/10.1097/QAI.0b013e318252f97e

McManus H; O'Connor CC; Boyd MA; Broom J; Russell D; Watson K; Roth N; Read PJ, 2012, 'Long-term survival in HIV positive patients with up to 15 years of antiretroviral therapy', PLoS One, vol. 7, pp. Article numbere48839, http://dx.doi.org/10.1371/journal.pone.0048839

Avihingsanon A; van der Lugt J; Singphore U; Gorowara M; Boyd MA; Ananworanich J; Phanuphak P; Burger DM; Ruxrungtham K, 2012, 'Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: A pilot study', AIDS Research and Human Retroviruses, vol. 28, pp. 1170 - 1176, http://dx.doi.org/10.1089/aid.2011.0247

Boyd MA; Mohapi L, 2012, 'STRETCHing delivery of HIV health services', Lancet, vol. 380, pp. 865 - 867, http://dx.doi.org/10.1016/S0140-6736(12)60952-0

Boyd MA, 2012, 'Dolutegravir — a promising antiretroviral in development', Lancet Infectious Diseases, vol. 12, pp. 90 - 91, http://dx.doi.org/10.1016/S1473-3099(11)70291-2

Byakwaga H; Purcell DJ; French MA; Amin J; Lewin S; Haskelberg H; Kelleher AD; Garsia RJ; Boyd MA; Cooper DA; Emery S, 2011, 'Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4 + T-cell response: A randomized controlled trial', Journal of Infectious Diseases, vol. 204, pp. 1532 - 1540, http://dx.doi.org/10.1093/infdis/jir559

Wilson DP; Grulich AE; Boyd MA, 2011, 'Overly optimistic forecasts of the impact of treatment as HIV prevention for men who have sex with men', Clinical Infectious Diseases, vol. 53, pp. 611 - 612, http://dx.doi.org/10.1093/cid/cir477

Revell ; Wang ; Boyd MA; Emery S; Pozniak A; de WF; Harrigan R; Montaner JSG; Lane C; Larder B, 2011, 'The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool', AIDS, vol. 25, pp. 1855 - 1863, http://dx.doi.org/10.1097/QAD.0b013e328349a9c2

Boyd MA; Hill AM, 2010, 'Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era', PharmacoEconomics, vol. 28, pp. 17 - 34, http://dx.doi.org/10.2165/11587420-000000000-00000

Boyd MA; Nwizu CA, 2010, 'Operational research in HIV priority areas: the African way.', Lancet, vol. 376, pp. 4 - 6, http://dx.doi.org/10.1016/S0140-6736(10)60972-5

Carey DL; Amin J; Boyd MA; Petoumenos K; Emery S, 2010, 'Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomised controlled trials', Journal of Antimicrobial Chemotherapy, vol. 65, pp. 1878 - 1888, http://dx.doi.org/10.1093/jac/dkq231

Zhou J; Li PCK; Kumarasamy N; Boyd MA; Chen YMA; Sirisanthana T; Sungkanuparph S; Oka S; Tau G; Phanuphak P; Saphonn V; Zhang FJ; Omar SFS; Lee CKC; Ditangco R; Merati TP; Lim PL; Choi JY; Law MG; Pujari S, 2010, 'Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD)', HIV Medicine, vol. 11, pp. 31 - 39, http://dx.doi.org/10.1111/j.1468-1293.2009.00738.x

Boyd MA, 2010, 'Current and future management of treatment failure in low- and middle-income countries', Current opinion in HIV & AIDS, vol. 5, pp. 83 - 89, http://dx.doi.org/10.1097/COH.0b013e328333b8c0

Boyd MA; Hill A, 2010, 'Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era', Pharmacoeconomics, vol. 28, pp. 17 - 34, http://dx.doi.org/10.2165/11587420-000000000-00000

Boyd MA, 2009, 'Improvements in antiretroviral therapy outcomes over calendar time', Current Opinion in HIV and AIDS, vol. 4, pp. 194 - 199, http://dx.doi.org/10.1097/COH.0b013e328329fc8d

Boyd M, 2009, 'Clinical research in low- And middle-income countries', Virtual Mentor, vol. 11, pp. 511 - 515, http://dx.doi.org/10.1001/virtualmentor.2009.11.7.jdsc1-0907

Boyd MA, 2009, 'Improvements in antiretroviral therapy outcomes over calendar time', Current opinion in HIV & AIDS, vol. 4, pp. 194 - 199, http://dx.doi.org/10.1097/COH.013e328329fc8d

Byakwaga H; Zhou J; Petoumenos K; Law MG; Boyd MA; Emery S; Cooper DA; Mallon PW, 2009, 'Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy', HIV Medicine, vol. 10, pp. 143 - 151, http://dx.doi.org/10.1111/j.1468-1293.2008.00663.x

Mcintyre GJ; Yu Y; Tran A; Jaramillo AB; Arndt AJ; Millington ML; Boyd MP; Elliott FA; Shen SW; Murray JM; Applegate TL, 2009, 'Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success', Virology Journal, vol. 6, pp. 184, http://dx.doi.org/10.1186/1743-422X-6-184

Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA, 2009, 'Evolution of CD4+T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression', AIDS Research and Human Retroviruses, vol. 25, pp. 569 - 576, http://dx.doi.org/10.1089/aid.2008.0149

Boyd MA; Emery S; Cooper DA, 2009, 'Antiretroviral roll-out: the problem of second-line therapy', Lancet, vol. 374, pp. 185 - 186, http://dx.doi.org/10.1016/S0140-6736(09)61313-1

Oelrichs R; Boyd M, 2008, 'Evidence and policy in the globalized response to AIDS', Current Opinion in HIV and AIDS, vol. 3, pp. 477 - 480, http://dx.doi.org/10.1097/COH.0b013e328303ba0b

Colebunders R; French M; Oelrichs R; Boyd M, 2008, 'Editorial introductions', Current Opinion in HIV and AIDS, vol. 3, http://dx.doi.org/10.1097/COH.0b013e32830890a4

Boyd MA; Truman M; Holes G; Anderson JA; Dwyer DE; Carr AD, 2008, 'A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study)', Antiviral Therapy, vol. 13, pp. 449 - 453

Boyd MA; Byakwaga H, 2008, 'Considering the benefits of disease-specific interventions on overall public health', Lancet Infectious Diseases, vol. 8, pp. 278 - 278, http://dx.doi.org/10.1016/S1473-3099(08)70080-X

Boyd MA; Pett SL, 2008, 'Experimental and clinical pharmacology - HIV fusion inhibitors: a review', Australian Prescriber, vol. 31, pp. 66 - 69, http://dx.doi.org/10.18773/austprescr.2008.040

Mackowiak PA; Boyd MA; Menon P; Graves S; Gordon DL, 2007, 'A Febrile Illness with Generalized Papular Rash Involving the Palms and Soles', Clinical Infectious Diseases, vol. 44, pp. 755 - 756, http://dx.doi.org/10.1086/511651

Boyd MA; Menon P; Graves S; Gordon DL, 2007, 'A febrile illness with generalized papular rash involving the palms and soles.', Clin Infect Dis, vol. 44, pp. 704 - 756, http://dx.doi.org/10.1086/511637

Autar R; Boyd MA; Wit F; Ruxrungtham K; Sankote J; Lange JM; Cooper DA; Phanuphak P; Burger DM; Reiss P, 2007, 'Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen', Antiviral Therapy, vol. 12, pp. 1265 - 1271

Kerr SJ; Duncombe CJ; Avihingsanon A; Ananworanich J; Boyd MA; Sopa B; Chuenyam T; Cooper DA; Lange JM; Phanuphak P; Ruxrungtham K, 2007, 'Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens.', Journal of the International Association of Physicians in AIDS Care, vol. 6, pp. 36 - 46, http://dx.doi.org/10.1177/1545109706295946

Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG, 2007, 'Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment', HIV Medicine, vol. 8, pp. 46 - 54, http://dx.doi.org/10.1111/j.1468-1293.2007.00427.x

Boyd MA; Cooper DA, 2007, 'Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research', AIDS, vol. 21, pp. S55 - S63, http://dx.doi.org/10.1097/01.aids.0000279707.01557.b2

Cooper DA; Cahn PE; Lewin S; Kaldor JM; McClure C; Kort R; Boyd MA, 2007, 'The Sydney Declaration: a call to scale up research', Lancet, vol. 370, pp. 7 - 8, http://dx.doi.org/10.1016/S0140-6736(07)61024-1

Boyd MA, 2007, 'Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?', Expert Opinion on Pharmacotherapy, vol. 8, pp. 957 - 964, http://dx.doi.org/10.1517/14656566.8.7.957

Boyd MA; Truman M; Hales GP; Anderson JS; Dwyer DE; Carr AD, 2007, 'A randomized study to evaluate injection site reactions (ISR) using three different mechanisms for delivery of enfuvirtide (ENF): a 27-gauge needle, a 31-gauge needle and a needle-free device', Antiviral Therapy, vol. 12, pp. L57 - L57, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000249773400105&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Snelling T; Ossowicz C; Boyd M, 2007, 'Co-infections in an HIV-infected man from Malawi.', Am J Trop Med Hyg, vol. 76, pp. 180 - 181, https://www.ncbi.nlm.nih.gov/pubmed/17255249

Boyd MA; Dixit N; Siangphoe U; Buss N; Salgo M; Lange J; Phanuphak P; Cooper DA; Perelson A; Ruxrungtham K, 2006, 'Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: A randomized, controlled trial (HIV-NAT 012)', Journal of Infectious Diseases, vol. 194, pp. 1319 - 1322, http://dx.doi.org/10.1086/508291

Boyd MA; Carr AD; Ruxrungtham K; Srasuebkul P; Bien D; Law MG; Wangsuphachart S; Krisanachinda A; Lerdlum S; Lange J; Phanuphak P; Cooper DA; Reiss P, 2006, 'Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to Ritonavir-boosted Indinavir and Efavirenz', Journal of Infectious Diseases, vol. 194, pp. 642 - 650, http://dx.doi.org/10.1086/505709

Boyd MA; Burger D; Phanuphak P; Cooper DA, 2006, 'Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis', AIDS, vol. 20, pp. 1083 - 1085, http://dx.doi.org/10.1097/01.aids.0000222090.52035.b2

Boyd MA; Siangphoe U; Ruxrungtham K; Reiss P; Mahanontharit A; Lange JM; Phanuphak P; Cooper DA; Burger D, 2006, 'The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity', Journal of Antimicrobial Chemotherapy, vol. 57, pp. 1161 - 1167, http://dx.doi.org/10.1093/jac/dkl112

Boyd MA; Srasuebkul P; Ruxrungtham K; Mackenzie P; Uchaipichat V; Stek M; Lange JM; Phanuphak P; Cooper DA; Udomuksorn W; Miners JO, 2006, 'Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir', Pharmacogenetics and Genomics, vol. 16, pp. 321 - 329, http://dx.doi.org/10.1097/01.fpc.0000197465.14340.d4

Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange JM; Cooper DA; Phanuphak P, 2006, 'Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).', Antiviral Therapy, vol. 11, pp. 223 - 232

Boyd M; Reiss P, 2006, 'The long-term consequences of antiretroviral therapy: a review.', J HIV Ther, vol. 11, pp. 26 - 35, https://www.ncbi.nlm.nih.gov/pubmed/16981593

Boyd M; Rogers W, 2006, 'Industry and bioethics: what price the relationship?', PLoS Med, vol. 3, pp. e281, http://dx.doi.org/10.1371/journal.pmed.0030281

Kong A; Koukourou A; Boyd M; Crowe G, 2006, 'Metastatic adenocarcinoma mimicking 'target sign' of cerebral tuberculosis.', J Clin Neurosci, vol. 13, pp. 955 - 958, http://dx.doi.org/10.1016/j.jocn.2005.11.039

Macpherson JL; Boyd MP; Arndt AJ; Todd AV; Ganning GC; Ely JA; Elliott F; Knop A; Raponi M; Murray JM; Gerlach W; Sun L; Penny R; Symonds GP; Carr AD; Cooper DA, 2005, 'Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients', Journal of Gene Medicine, vol. 7, pp. 552 - 564, http://dx.doi.org/10.1002/jgm.705

Boyd MA; Siangphoe U; Ruxrungtham K; Duncombe CJ; Stek M; Lange JM; Cooper DA; Phanuphak P, 2005, 'Indinavir/ritonavir 800/100mg bid and efavirenz 600mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009', HIV Medicine, vol. 6, pp. 410 - 420, http://dx.doi.org/10.1111/j.1468-1293.2005.00327.x

Boyd MA; Mootsikapun P; Burger D; Chuenyam T; Ubolyam S; Mahanontharit A; Sangkote J; Bunyaprawit P; Horsakulchai M; Lange JM; Cooper DA; Phanuphak P; Ruxrungtham K, 2005, 'Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients', Antiviral Therapy, vol. 10, pp. 301 - 307

Ananworanich J; Cheunyam T; Teeratakulpisarn S; Boyd MA; Ruxrungtham K; Lange PJ; Cooper PD; Phanuphak PP, 2004, 'Creation of a drug fund for post-clinical trial access to antiretrovirals', Lancet, vol. 364, pp. 101 - 102, http://dx.doi.org/10.1016/S0140-6736(04)16596-3

Ruxrungtham K; Boyd MA; Bellibas S; Zhang X; Dorr A; Kolis S; Kinchelow T; Buss N; Patel IH, 2004, 'Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients', Journal of Clinical Pharmacology, vol. 44, pp. 793 - 802, http://dx.doi.org/10.1177/0091270004266489

Law WP; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA; Dore GJ, 2004, 'Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort', AIDS, vol. 18, pp. 1169 - 1177, http://dx.doi.org/10.1097/00002030-200405210-00010

Boyd MA; Zhang X; Dorr A; Ruxrungtham K; Kolis S; Nieforth K; Kinchelow T; Buss N; Patel IH, 2003, 'Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide', Journal of Clinical Pharmacology, vol. 43, pp. 1382 - 1391, http://dx.doi.org/10.1177/0091270003259220

Law WP; Dore GJ; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA, 2003, 'Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001', AIDS, vol. 17, pp. 2191 - 2199, http://dx.doi.org/10.1097/00002030-200310170-00007

Boyd MA; Aarnoutse RE; Ruxrungtham K; Stek M; van Heeswijk RP; Lange JM; Cooper DA; Phanuphak P; Burger DM, 2003, 'Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects', Journal of Acquired Immune Deficiency Syndrome, vol. 34, pp. 134 - 139, http://dx.doi.org/10.1097/00126334-200310010-00003

Burger D; Boyd M; Duncombe CJ; Felderhof M; Mahanontharit A; Ruxrungtham K; Ubolyam S; Stek M; Cooper DA; Lange JM; Phanuphak P; Reiss P, 2003, 'Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients', Journal of Antimicrobial Chemotherapy, vol. 51, pp. 1231 - 1238, http://dx.doi.org/10.1093/jac/dkg198

Chadwick M; Boyd MA; Cathers B, 1997, 'A water quality modelling tutorial using SIMULINK', in MODSIM 1997: International Congress on Modelling and Simulation, MODSIM 1997: International Congress on Modelling and Simulation, University of Tasmania, Hobart, presented at MODSIM 1997: International Congress on Modelling and Simulation, University of Tasmania, Hobart, 08 December 1997 - 11 December 1997

Boyd MA; Cathers B; Chadwick M; Craig E, 1996, 'Developing a set of teaching exercises in ennvironmental engineering modelling', in 8th Australasian Association for Engineering Education Conference and Convention, 8th Australasian Association for Engineering Education Conference and Convention, University of New South Wales, presented at 8th Australasian Association for Engineering Education Conference and Convention, University of New South Wales, 15 December 1996 - 18 December 1996